Core Viewpoint - Rosen Law Firm is urging investors of Jasper Therapeutics, Inc. to contact them regarding a class action lawsuit due to allegations of misleading business operations [1][2]. Summary by Sections Allegations - The lawsuit claims that Jasper Therapeutics made false and misleading statements, including: - Lack of necessary controls and procedures for third-party manufacturers to comply with cGMP regulations [3]. - Increased risk of confounding results in ongoing studies, negatively impacting regulatory and commercial prospects of products like briquilimab [3]. - Potential for disruptive cost-reduction measures due to the aforementioned failures [3]. - Overstated business and financial prospects, as well as clinical and commercial prospects of briquilimab [3]. - Public statements made by defendants were materially false and misleading [3]. Class Action Participation - Investors may be eligible to participate in the class action against Jasper Therapeutics, with a deadline to file motions for lead plaintiff by November 18, 2025 [4]. - Investors do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]. Rosen Law Firm Background - Rosen Law Firm is recognized for its commitment to shareholder rights litigation, having recovered over $1 billion for shareholders since its inception [6].

Skip to Main Content Skip to Search Skip to... Select Read Next This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. (Illustration by Guillem Casasús) China's Stocks Are Flying as Beijing Doubles Down on Tech. Why the Economy Is Still Struggling. China's commitment to innovat ...

Core Insights - Investors should consider adding stocks with strong liquidity to their portfolios, as liquidity indicates a company's ability to meet short-term obligations and supports business expansion [1][2] - Four top-ranked stocks recommended for investment include EverQuote, Inc. (EVER), Amicus Therapeutics, Inc. (FOLD), Lam Research Corporation (LRCX), and Cboe Global Markets, Inc. (CBOE) [2][9] Liquidity Measures - Current Ratio: Measures current assets against current liabilities; a ratio below 1 indicates more liabilities than assets, while a range of 1-3 is ideal [4] - Quick Ratio: Indicates a company's ability to pay short-term obligations, with a desirable ratio of more than 1 [5] - Cash Ratio: The most conservative measure, focusing on cash and equivalents relative to current liabilities; a ratio greater than 1 is desirable but may indicate inefficiency [6] Screening Parameters - Asset Utilization: A measure of efficiency, calculated as total sales over the last 12 months divided by the average total assets; companies with a ratio higher than their industry average are considered efficient [7][8] - Growth Score: A proprietary score added to ensure that liquid and efficient stocks also have solid growth potential [8] Company-Specific Insights - **EverQuote, Inc. (EVER)**: Reported revenues of $173.9 million, a 20% year-over-year increase; projected fourth-quarter revenues between $174-$180 million [12][13] - **Amicus Therapeutics, Inc. (FOLD)**: Revenues of $169.1 million, a 19% year-over-year increase; expects total revenues to grow by 15-22% in 2025 [14][15] - **Lam Research Corporation (LRCX)**: Reported revenues of $5.32 billion, a 28% increase year-over-year; projects second-quarter revenues of $5.2 billion [16][17] - **Cboe Global Markets, Inc. (CBOE)**: Achieved record revenues of $605.5 million, a 14% year-over-year increase; raised 2025 organic revenue growth target to low double-digit to mid-teens [18][19]

Visa Sponsorship Landscape - The Trump administration has increased the H-1B visa application fee to $100,000, creating uncertainty for organizations regarding sponsorship expenses and procedures [2][8] - The proportion of full-time positions offering visa sponsorship has dropped significantly from 10.9% to 1.9% between 2023 and 2025, with the technology sector experiencing the most substantial reduction [4][9] - Major companies like Walmart Inc. have suspended job offers for candidates requiring H-1B visas, reflecting a broader trend of reduced willingness to sponsor international students [8][9] Employment Challenges for International Students - International students are facing increased difficulties in securing employment, with many organizations declining to interview candidates upon learning of their visa sponsorship needs [4][8] - The current job market for professional roles is challenging, with a slowdown in recruitment processes across white-collar sectors, including technology [5][9] - Organizations are exhibiting heightened caution in their recruitment activities, leading international students to apply for significantly more positions than before [5][9] Economic Contributions of Immigrants - A study by the Manhattan Institute indicates that Indian immigrants contribute positively to the US economy, with each Indian immigrant reducing the national debt by an average of $1.6 million over three decades [7][9] - This research challenges the prevailing assumptions about the economic burden of immigration, highlighting the significant GDP impact of Indian immigrants compared to other groups [7][9]

Core Insights - Elicio Therapeutics announced new immunogenicity data from the Phase 2 AMPLIFY-7P trial for ELI-002 7P, showing strong T cell responses in patients with mKRAS pancreatic ductal adenocarcinoma [1][3][5] - The company also presented preclinical data for ELI-004, indicating its potential to eradicate advanced solid tumors in over 90% of cases [1][8] ELI-002 7P Trial Results - In the AMPLIFY-7P trial, 99% of 90 evaluable patients achieved robust mKRAS-specific T cell responses, with a mean increase of 145-fold over baseline [4][5] - 85% of patients exhibited combined CD4 and CD8 T cell activation, which correlates with clinical activity [5] - 67% of patients responded to all seven mKRAS epitopes, with over 80% response rates to each individual KRAS mutation [4][5] ELI-004 Preclinical Data - ELI-004 demonstrated complete tumor eradication in over 90% of cases in preclinical studies, suggesting long-term protection against recurrence [3][8] - The efficacy of ELI-004 was linked to the presence of CD8 T cells and effective lymphocyte trafficking from lymph nodes [8] HLA Diversity and T Cell Responses - High-resolution HLA typing revealed a diverse HLA repertoire among patients, with 1,132 unique HLAs identified [6] - No significant associations were found between specific HLA types and the magnitude of mKRAS-specific T cell responses, indicating broad applicability of ELI-002 7P [6] Company Overview - Elicio Therapeutics focuses on developing novel immunotherapies targeting high-prevalence cancers, particularly those driven by KRAS mutations [15] - The company's AMP technology aims to enhance immune responses by delivering immunotherapeutics directly to lymph nodes [12][14]

Core Insights - BioAtla, Inc. presented clinical data showing that Mecbotamab Vedotin (Mec-V) achieved a median overall survival (OS) of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma, compared to approximately 12 months with approved agents [1][4][7] - The safety profile of Mec-V, both as a monotherapy and in combination with anti-PD-1 antibody, was manageable and consistent with its mechanism of selectively targeting the tumor microenvironment [1][2][4] Clinical Trial Details - In a Phase 2 clinical trial, 79 patients with advanced soft tissue sarcomas were treated with Mec-V, either as monotherapy (n=54) or in combination with anti-PD-1 antibody (n=25) [3] - A focused efficacy analysis was conducted on a subset of 44 patients who had treatment-refractory leiomyosarcoma, liposarcoma, or undifferentiated pleomorphic sarcoma [3] Efficacy and Safety Data - The median OS was 21.5 months across all patients, with 22.9 months in the combination arm and 18.4 months in the monotherapy arm [7] - The 12-month OS rate was 73%, significantly higher than the approximately 50% historically reported for approved agents in similar populations [7] - The disease control rate (DCR) was 52% across all patients, with two patients achieving partial responses [7] - Adverse events were generally low-grade and manageable, with no treatment-related deaths reported [7] Presentation Information - The data was presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlighting the potential of Mec-V to extend survival in patients with limited treatment options [1][6]

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab compared to competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

Core Insights - Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health [1][3] - The company will participate in two investor conferences in November 2025, showcasing its leadership and ongoing projects [2] Conference Participation - At the Guggenheim Annual Healthcare Innovation Conference on November 11, 2025, Paul Bolno, MD, MBA, President and CEO, will engage in an analyst-led fireside chat at 10:00 a.m. ET [2] - At the Jefferies London Healthcare Conference on November 20, 2025, Dr. Bolno will participate in an analyst-led fireside chat at 8:30 a.m. GMT / 3:30 a.m. ET and in the "Anti-Obesity Panel" at 9:00 a.m. GMT / 4:00 a.m. ET [2] Company Overview - Wave Life Sciences utilizes its RNA medicines platform, PRISM, which integrates various modalities and innovations in chemistry to address both rare and common disorders [3] - The company's pipeline includes clinical programs targeting obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs [3] - Wave Life Sciences is headquartered in Cambridge, MA, and is committed to advancing human health by overcoming disease burdens [3]

Core Insights - ALX Oncology reported financial results for Q3 2025, highlighting advancements in its clinical pipeline and financial position [1][3][13] Financial Performance - Cash, cash equivalents, and investments as of September 30, 2025, were $66.5 million, sufficient to fund operations into Q1 2027 [13][18] - R&D expenses for Q3 2025 were $17.4 million, a decrease from $26.5 million in Q3 2024, primarily due to reduced stock-based compensation and clinical development costs [13][16] - GAAP net loss for Q3 2025 was $22.1 million, or $0.41 per share, compared to a net loss of $30.7 million, or $0.58 per share, in Q3 2024 [13][16] Clinical Developments - Data from the ASPEN-06 trial showed that evorpacept combined with trastuzumab, ramucirumab, and paclitaxel achieved a 65.0% objective response rate in HER2-positive gastric cancer patients with high CD47 expression [5][6] - The Phase 2 ASPEN-09-Breast Cancer trial is set to begin enrollment in Q4 2025, evaluating evorpacept's efficacy based on CD47 expression levels [4][8] - The Phase 1 trial for ALX2004, an EGFR-targeted antibody-drug conjugate, is currently enrolling patients and is on track to deliver initial safety data in the first half of 2026 [4][9] Upcoming Milestones - Initial safety data for ALX2004 is expected in 1H 2026, with interim data for ASPEN-09-Breast Cancer anticipated in Q3 2026 [4][7] - The company appointed Barbara Klencke, M.D., as Chief Medical Officer, bringing over 30 years of experience in oncology drug development [4][8]

Core Insights - Assembly Biosciences, Inc. announced positive Phase 1b clinical data for its investigational capsid assembly modulator ABI-4334, showcasing a favorable safety profile and significant reductions in viral nucleic acids [1][2][3] Group 1: Clinical Data - The Phase 1b study involved two cohorts of predominantly HBeAg-negative subjects, evaluating 150 mg and 400 mg oral doses of ABI-4334 administered once daily for 28 days [3] - ABI-4334 demonstrated well-tolerated results at both dose levels, with multi-log declines in hepatitis B virus (HBV) DNA and pregenomic RNA (pgRNA) observed, indicating effective suppression of viral replication [3] - The study results support the potential of ABI-4334 to maximize antiviral activity as part of multi-drug combination regimens targeting chronic hepatitis B infection [2][3] Group 2: Presentation and Collaboration - The complete Phase 1b data was presented in a late-breaking poster at the American Association for the Study of Liver Diseases (AASLD) conference, marking the first scientific presentation of these findings [1][2] - Under a collaboration agreement with Gilead Sciences, Gilead has the option to obtain an exclusive license for further development and commercialization of ABI-4334 after reviewing the data package post-Phase 1b study [4]